Allurion stockholders approve reverse stock split, equity plan amendment, and other proposals at 2025 annual meeting

ALLURION TECHNOLOGIES, INC.

Re-elected directors Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to serve until 2028 annual meeting.
Ratified Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2025.
Approved amendment to 2023 Stock Option and Incentive Plan, increasing share reserve and allowing repricing of outstanding options.
Approved issuance of common stock upon conversion of Series B Preferred and exercise of private placement warrants for NYSE compliance.
Approved reverse stock split amendment in range 1:1.5 to 1:20; Board to set exact ratio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.